Although the etiology of prostate enlargement is not clear, it cannot be ruled out that prostatitis is the initiating factor for prostate enlargement. This is because a chronic inflammatory response is evident in the pathology of prostate enlargement regardless of the presence of LUTS in the patient. Infiltration of T and B cells was observed in both the epidermal and stromal cells of the prostate. It is therefore reasonable to assume that prostatic hyperplasia is an immune-mediated inflammatory response. So there is a correlation between prostatitis, prostatic hyperplasia and LUTS observed in the relevant literature. And it is believed that chronic prostatitis is a high risk factor for prostate disease course and acute urinary retention. Based on the correlation between prostatitis and LUTS, it is believed that anti-inflammatory treatment is clinically significant for the relief of prostate enlargement symptoms. Based on the above theory, recent recent related literature elaborates several basic ideas: 1. Prostate inflammation is associated with LUTS, and the more severe the inflammation, the more severe the LUTS symptoms. Some investigators have constructed models of prostatitis by injecting E. coli into the prostate ducts of rats, and the correlation between infection and prostate enlargement and prostate cancer has been observed through the animal models constructed. It has been theorized that inflammation is a causative factor in promoting prostate enlargement, so it has been suggested that antibiotics can be used to treat prostate enlargement, and it is further suggested that the combination of antibiotics to treat prostate enlargement is more effective than ā-blockers alone. This point of view with our clinical use guidance significance: firstly proposed a new view of applying antibiotics alone to treat prostatic hyperplasia. Secondly, it further provides a solid theoretical basis for the simultaneous application of ā receptor blockers in our clinical treatment of prostatitis. Third, antibiotic therapy should be added to the treatment of prostatic hyperplasia or the role of antibiotics should not be completely ignored. 2. The heavier the inflammation of the prostate the lower the urinary flow rate, accompanied by a larger prostate volume. The heavier the inflammation of the prostate, the lower the maximum and average urine flow rate of the patient. And the inflammation of the patient’s prostate and the size of the prostate are correlated. This is further proof of the saying that “running water does not rot and the pivot does not worm”. Inflammation can lead to a lower urinary flow rate, and poor drainage can in turn worsen inflammation. Of course there is a clear correlation between prostate volume and LUTS, with the larger the volume the more pronounced the LUTS, so the literature suggests that prostate inflammation may influence the relationship rather than be the determining factor. Because of clinical observations, IPSS scores and QOL scores do not correlate with inflammation of the prostate. 3. receptor blockers for prostatitis Some studies have concluded that the combination of ā receptor blockers for the treatment of prostatitis is not better the longer the application time. Longer time did not give better LUTS symptom relief. However, the higher the patient’s IPSS score and the more severe the symptoms, the better the treatment effect of ā-blockers. This may be related to the efficacy of ā-blockers in relieving the symptoms of prostate enlargement. In conclusion, by looking again at the correlation between prostate inflammation, prostate enlargement, and LUTS, we gained further insight into the relationship between the three. The three may interact with each other as cause and effect. Therefore, in clinical work, the three cannot be completely separated from each other. When treating one of the problems, the other two need to be considered. Only by combining the three organically can we better solve the clinical problems of patients.